ArticleChest2026
Aspergillus fumigatus Sensitization Is Associated With High-Risk Bronchiectasis.
Article in Chest, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFungal sensitization is an increasingly recognized endophenotype in chronic respiratory disease; however, its role in bronchiectasis remains poorly defined. This study aimed to provide the most comprehensive evaluation to date of fungal sensitization and its clinical relevance in bronchiectasis using an expanded panel of crude and recombinant fungal allergens. RESEARCH QUESTION: What are the prevalence and clinical implications of fungal sensitization in bronchiectasis? STUDY DESIGN AND
methodsAn international, multicenter evaluation of fungal sensitization was conducted across 6 tertiary centers in 4 countries (Singapore, Malaysia, the United Kingdom, and Italy), prospectively recruiting 277 individuals with bronchiectasis. Using a comprehensive, expanded allergen panel including 11 crude and 24 recombinant fungal allergens (total of 35 allergens and 9,695 individual assays), sensitization responses were assessed in relation to clinical characteristics, exacerbation frequency, and geographic origin. Low baseline exacerbations were defined as < 3 and high baseline exacerbations as ≥ 3 in the preceding 12 months of study recruitment.
resultsOur results showed that sensitization to recombinant Aspergillus fumigatus (rAsp f) was linked to bronchiectasis severity. Measurable responses to rAsp f allergens 12, 15, and 17 were associated with severe (hospitalized) exacerbations, particularly in those with low baseline exacerbations (low risk). "Sensitized" low-risk individuals exhibited significantly greater disease severity and higher occurrence of bronchiectasis-COPD overlap compared with nonsensitized, low-risk individuals, a relationship absent in those with high baseline exacerbations. Polysensitization to the same allergens conferred further additional risks of severe (hospitalized) exacerbations. Notably, Asian patients sensitized to rAsp f allergens 12, 15, and 17 exhibited the poorest clinical outcomes with increased symptoms, poorer lung function, and severe disease.
interpretationThis study shows that A fumigatus sensitization, particularly to rAsp f allergens 12, 15, and 17, is a clinically significant and potentially treatable trait in bronchiectasis. This finding is of highest relevance in individuals with lower baseline exacerbation frequency and of Asian descent.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.